Contents of plasma М2-pyruvate kinase (M2-РК) in patients with inflammatory bowel diseases
Aim of investigation. Assessment of М2-pyruvate kinase level (M2-РК) at patients with ulcerative colitis (UC) and Crohn’s disease (CD) and its relation to course, clinical and endoscopical activity of disease.Material and methods. Overall 70 patients were investigated: 42 – with UC, 15 – with CD, 13...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Gastro LLC
2010-11-01
|
| Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| Subjects: | |
| Online Access: | https://www.gastro-j.ru/jour/article/view/1571 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Aim of investigation. Assessment of М2-pyruvate kinase level (M2-РК) at patients with ulcerative colitis (UC) and Crohn’s disease (CD) and its relation to course, clinical and endoscopical activity of disease.Material and methods. Overall 70 patients were investigated: 42 – with UC, 15 – with CD, 13 – with irritable bowel syndrome (IBS) and 10 healthy patients. Blood plasma concentration of M2-РК was determined by solid-phase sandwich method of enzyme-linked immunoassay with application of «ScheBo» (Germany) test-systems.Results. The level of M2-РК in patients with UC, CD, IBS and healthy persons was 29,1±3,0, 17,3±1,5, 7,9±1,6 and 7,0±1,5 U/ml respectively (р<0,05 – for UC and CD in comparison to IBS and control group and for UC in comparison to CD). The level of M2-РК considerably raised in patients with severe (45,9±6,4 U/ml) and moderate (20,9±3,2 U/ml) UC, including steroid-resistant patients (61,5±6,2 U/ml), in comparison to patients in remission (11,0±1,8 U/ml, р><0,05) and at patients with chronic continuous course in comparison to chronic relapsing course (40,3±5,0 and 22,7±3,8 U/ml, р><0,05). The level of M2-РК had the strong tendency to increase with progression of endoscopic activity of UC. Increase of M2-РК concentration (М±σ of the control group, р><0,05) was observed in 76,2% of UC patients, at 73,3% of patients with CD and in 15,4% of patients with IBS.>< 0,05 – for UC and CD in comparison to IBS and control group and for UC in comparison to CD). The level of M2-РК considerably raised in patients with severe (45,9±6,4 U/ml) and moderate (20,9±3,2 U/ml) UC, including steroid-resistant patients (61,5±6,2 U/ml), in comparison to patients in remission (11,0±1,8 U/ml, р<0,05) and at patients with chronic continuous course in comparison to chronic relapsing course (40,3±5,0 and 22,7±3,8 U/ml, р><0,05). The level of M2-РК had the strong tendency to increase with progression of endoscopic activity of UC. Increase of M2-РК concentration (М±σ of the control group, р><0,05) was observed in 76,2% of UC patients, at 73,3% of patients with CD and in 15,4% of patients with IBS.>< 0,05) and at patients with chronic continuous course in comparison to chronic relapsing course (40,3±5,0 and 22,7±3,8 U/ml, р< 0,05). The level of M2-РК had the strong tendency to increase with progression of endoscopic activity of UC. Increase of M2-РК concentration (М±σ of the control group, р<0,05) was observed in 76,2% of UC patients, at 73,3% of patients with CD and in 15,4% of patients with IBS.>< 0,05) was observed in 76,2% of UC patients, at 73,3% of patients with CD and in 15,4% of patients with IBS.Conclusions. Blood level of M2-РК of patients with UC and CD increases considerably. Elevation of M2-РК level at patients with UC is associated to enhancement of clinical and endoscopical activity, chronic continuous course and steroid-resistance. |
|---|---|
| ISSN: | 1382-4376 2658-6673 |